 News
Archive
Latest News
| August
27, 2010 |
MBC Pharma, Inc. awarded an
SBIR Phase II grant ($1,795,054) to
investigate new compounds for prostate cancer
(read more)
|
| October
7, 2009 |
MBC Pharma, Inc. announces
issuance of a
key patent (read more)
|
| October
27, 2008 |
MBC Pharma, Inc. awarded an
SBIR Phase
II grant ($758,000) to investigate new
compounds for multiple myeloma (read more)
|
| November
30, 2007 |
MBC Pharma secures $1.8M in
private
financing
|
| June 29,
2007 |
MBC Pharma conducts a
successful
pre-IND meeting with FDA to validate
development plan for MBC-11 for
treatment of Cancer Induced Bone Diseases |
| June 6,
2007 |
MBC Pharma received $100,000
NIH SBIR
grant "Novel bisphosphonates for prostate
cancer therapy" |
| March,
2006 |
MBC Pharma presents latest results on
vtamin B6 derivative of
alendronate (MBC-31) on Eighth and
Valedictory Workshop on
Bisphosphonates, Davos, Switzerland, March
22-24, 2006
|
| January,
2006 |
MBC Pharma
newsletter |
| May 24,
2005 |
MBC Pharma awarded US Patent
6,896,781 B2 |
| April 1,
2005 |
Mayo
Clinic and MBC Pharma submit phase 2 STTR
grant application to NIH
entitled "Novel bisphosphonates for breast
cancer therapy"
|
|
